The identification of the most efficient method for whole central nervous system targeting that
is translatable to humans and the safest route of adeno-associated virus (AAV) …

Injection of adeno-associated virus (AAV) into the cerebrospinal fluid (CSF) offers a means
to achieve widespread transgene delivery to the central nervous system, where the doses …

The present study was designed to characterize transduction of non-human primate brain
and spinal cord with AAV5 viral vector after parenchymal delivery. AAV5-CAG-GFP (1× 10 …

Various administration routes of adeno-associated virus (AAV)-based gene therapy have
been examined to target the central nervous system to answer the question what the most …

Effective in vivo use of adeno-associated virus (AAV)-based vectors to achieve gene-specific
silencing or upregulation in the central nervous system has been limited by the inability to …

Gene therapy clinical trials for neurological disorders are ongoing using intrathecal injection
of adeno-associated virus (AAV) vector directly into the cerebral spinal fluid. Preliminary …

Several attempts have been made to discover the ideal vector for gene therapy in central
nervous system (CNS). Adeno-associated viruses (AAVs) are currently the preferred vehicle …

Introduction: Straightforward studies compared adeno-associated virus (AAV) serotypes to
determine the most appropriate one for robust expression in the CNS. AAV9 was efficient …

© The American Society of Gene Therapy commentary species, probably as a result of
differential expression of receptors across species. For instance, direct administration of …

The present study builds on previous work showing that infusion of adeno-associated virus
type 9 (AAV9) into the cisterna magna (CM) of nonhuman primates resulted in widespread …